Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy

被引:113
作者
Miller, Mark A. [1 ]
Louie, Thomas [2 ]
Mullane, Kathleen [3 ]
Weiss, Karl [4 ]
Lentnek, Arnold [5 ]
Golan, Yoav [6 ]
Kean, Yin [7 ]
Sears, Pam [7 ]
机构
[1] McGill Univ, Jewish Gen Hosp, Div Infect Dis, Montreal, PQ H3T 1E2, Canada
[2] Univ Calgary, Calgary, AB, Canada
[3] Univ Chicago, Chicago, IL 60637 USA
[4] Hop Maison Neuve Rosemont, Montreal, PQ, Canada
[5] Wellstar Infect Dis, Marietta, GA USA
[6] Tufts Med Ctr, Boston, MA USA
[7] Optimer Pharmaceut Inc, San Diego, CA USA
关键词
VANCOMYCIN; DISEASE; METRONIDAZOLE; FIDAXOMICIN; GUIDELINES; OUTBREAK; DIARRHEA; SOCIETY;
D O I
10.1186/1471-2334-13-148
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Clostridium difficile infection (CDI) continues to be a frequent and potentially severe infection. There is currently no validated clinical tool for use at the time of CDI diagnosis to categorize patients in order to predict response to therapy. Methods: Six clinical and laboratory variables, measured at the time of CDI diagnosis, were combined in order to assess their correlation with treatment response in a large CDI clinical trial database (derivation cohort). The final categorization scheme was chosen in order to maximize the number of categories (discrimination) while maintaining a high correlation with clinical cure assessed two days after the end of therapy. Validation of the derived scoring scheme was done on a second large CDI clinical trial database (validation cohort). A third comparison was done on the two pooled databases (pooled cohort). Results: In the derivation cohort, the best discrimination and correlation with cure was seen with a five-component ATLAS score (age, treatment with systemic antibiotics, leukocyte count, albumin and serum creatinine as a measure of renal function), which divided CDI patients into 11 groups (scores of 0 to 10 inclusive) and was highly correlated with treatment outcome (R-2=0.95; P<0.001). This scheme showed excellent prediction of cure in the validation cohort (overall Kappa=952%; P<0.0001), as well as in the pooled cohort, regardless of treatment (fidaxomicin or vancomycin). Conclusions: A combination of five simple and commonly available clinical and laboratory variables measured at the time of CDI diagnosis, combined into a scoring system (ATLAS), are able to accurately predict treatment response to CDI therapy. The ATLAS scoring system may be useful in stratifying CDI patients so that appropriate therapies can be chosen to maximize cure rates, as well as for categorization of patients in CDI therapeutic studies in order allow comparisons of patient groups.
引用
收藏
页数:7
相关论文
共 23 条
[1]  
[Anonymous], 2011, INFECT DIS CLIN PRAC
[2]  
[Anonymous], 2011, UPHS GUIDELINES ANTI
[3]  
[Anonymous], 47 ANN INT C ANT AG
[4]   European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI) [J].
Bauer, M. P. ;
Kuijper, E. J. ;
van Dissel, J. T. .
CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 (12) :1067-1079
[5]   Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system [J].
Belmares, Jaime ;
Gerding, Dale N. ;
Parada, Jorge P. ;
Miskevics, Scott ;
Weaver, Frances ;
Johnson, Stuart .
JOURNAL OF INFECTION, 2007, 55 (06) :495-501
[6]  
Brouwers MC, 2011, EXPERT REV PHARM OUT, V11, P151, DOI [10.1586/erp.11.11, 10.1586/ERP.11.11]
[7]   Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) [J].
Cohen, Stuart H. ;
Gerding, Dale N. ;
Johnson, Stuart ;
Kelly, Ciaran P. ;
Loo, Vivian G. ;
McDonald, L. Clifford ;
Pepin, Jacques ;
Wilcox, Mark H. .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2010, 31 (05) :431-455
[8]   EXPLAINING BASIC CATEGORIES - FEATURE PREDICTABILITY AND INFORMATION [J].
CORTER, JE ;
GLUCK, MA .
PSYCHOLOGICAL BULLETIN, 1992, 111 (02) :291-303
[9]   Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials [J].
Crook, Derrick W. ;
Walker, A. Sarah ;
Kean, Yin ;
Weiss, Karl ;
Cornely, Oliver A. ;
Miller, Mark A. ;
Esposito, Roberto ;
Louie, Thomas J. ;
Stoesser, Nicole E. ;
Young, Bernadette C. ;
Angus, Brian J. ;
Gorbach, Sherwood L. ;
Peto, Timothy E. A. .
CLINICAL INFECTIOUS DISEASES, 2012, 55 :S93-S103
[10]   Comparison of Clinical Severity Score Indices for Clostridium difficile Infection [J].
Fujitani, Shigeki ;
George, W. Lance ;
Murthy, A. Rekha .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2011, 32 (03) :220-228